CoChat
Sign Up
Cited by 25

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo

Fu, Ting, Guan, YangYang, Xu, Junjie, Wang, Yan·2017·Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
DOI 10.1016/j.bbalip.2017.05.002PMC PMC5514539
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbalip.2017.05.002

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PCSK9 does not have an effect on hepatic LRP1 degradation in WT mice.

    “although PCSK9 does not have an effect on hepatic LRP1 degradation in WT mice (17,37,38)”

    From The hepatic WASH complex is required for efficient plasma LDL and HDL cholesterol clearance (2019) · cites this paper as [37]

    The Results section (‘PCSK9-mediated LDLR Degradation in the Liver Does Not Require LRP1’) reports that PCSK9 infusion did not affect hepatic LRP1 levels in WT mice, and the Discussion reiterates this finding. The paper reports protein levels, not a direct measurement of LRP1 degradation, so the claim is more specific than the evidence. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

  • A role for PCSK9 in hepatic LRP1 degradation in WT mice or in hepatic COMMD1-deficient mice could not be confirmed.

    “However, we and others could not confirm a role for PCSK9 in hepatic LRP1 degradation in WT mice, nor in hepatic COMMD1-deficient mice (17,37,38).”

    From The hepatic WASH complex is required for efficient plasma LDL and HDL cholesterol clearance (2019) · cites this paper as [37]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 43

  1. Seidah, 2003, The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation, Proc. Natl. Acad. Sci. U. S. A., 100, 928, 10.1073/pnas.0335507100 · DOI · Paper page
  2. Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat. Genet., 34, 154, 10.1038/ng1161 · DOI · Paper page
  3. Timms, 2004, A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree, Hum. Genet., 114, 349, 10.1007/s00439-003-1071-9 · DOI
  4. Leren, 2004, Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia, Clin. Genet., 65, 419, 10.1111/j.0009-9163.2004.0238.x · DOI
  5. Park, 2004, Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver, J. Biol. Chem., 279, 50630, 10.1074/jbc.M410077200 · DOI · Paper page
  6. Benjannet, 2004, NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the LDLR and LDL-cholesterol, J. Biol. Chem., 279, 48865, 10.1074/jbc.M409699200 · DOI · Paper page
  7. Maxwell, 2004, Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype, Proc. Natl. Acad. Sci. U. S. A., 101, 7100, 10.1073/pnas.0402133101 · DOI · Paper page
  8. Dietschy, 1993, Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans, J. Lipid Res., 34, 1637, 10.1016/S0022-2275(20)35728-X · DOI · Paper page
  9. Brown, 1986, A receptor-mediated pathway for cholesterol homeostasis, Science, 232, 34, 10.1126/science.3513311 · DOI · Paper page
  10. Rudenko, 2002, Structure of the LDL receptor extracellular domain at endosomal pH, Science, 298, 2353, 10.1126/science.1078124 · DOI · Paper page
  11. Brown, 1982, Recycling of cell-surface receptors: observations from the LDL receptor system, Cold Spring Harb. Symp. Quant. Biol., 46, 713, 10.1101/SQB.1982.046.01.068 · DOI
  12. Wang, 2012, Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR, J. Lipid Res., 53, 1932, 10.1194/jlr.M028563 · DOI · Paper page
  13. Piper, 2007, The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol, Structure, 15, 545, 10.1016/j.str.2007.04.004 · DOI · Paper page
  14. Zhang, 2007, Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation, The Journal of biological chemistry, 282, 18602, 10.1074/jbc.M702027200 · DOI · Paper page
  15. Holla, 2011, Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors, J. Lipid Res., 52, 1787, 10.1194/jlr.M018093 · DOI · Paper page
  16. Tveten, 2012, Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification, Hum. Mol. Genet., 21, 1402, 10.1093/hmg/ddr578 · DOI · Paper page
  17. Fisher, 2007, Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation, J. Biol. Chem., 282, 20502, 10.1074/jbc.M701634200 · DOI · Paper page
  18. Cunningham, 2007, Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia, Nat. Struct. Mol. Biol., 14, 413, 10.1038/nsmb1235 · DOI · Paper page
  19. Bottomley, 2009, Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants, J. Biol. Chem., 284, 1313, 10.1074/jbc.M808363200 · DOI
  20. Surdo, 2011, Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH, EMBO Rep., 12, 1300, 10.1038/embor.2011.205 · DOI · Paper page
  21. Zhang, 2008, Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor, Proc. Natl. Acad. Sci. U. S. A., 105, 13045, 10.1073/pnas.0806312105 · DOI · Paper page
  22. Zheng, 2006, The amyloid precursor protein: beyond amyloid, Mol. Neurodegener., 1, 5, 10.1186/1750-1326-1-5 · DOI
  23. von Koch, 1997, Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice, Neurobiol. Aging, 18, 661, 10.1016/S0197-4580(97)00151-6 · DOI
  24. Thinakaran, 2008, Amyloid precursor protein trafficking, processing, and function, J. Biol. Chem., 283, 29615, 10.1074/jbc.R800019200 · DOI · Paper page
  25. Davis, 1987, The low density lipoprotein receptor. Identification of amino acids in cytoplasmic domain required for rapid endocytosis, J. Biol. Chem., 262, 4075, 10.1016/S0021-9258(18)61313-4 · DOI · Paper page
  26. Herz, 1988, Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor, EMBO J., 7, 4119, 10.1002/j.1460-2075.1988.tb03306.x · DOI
  27. Tuli, 2008, Amyloid precursor-like protein 2 increases the endocytosis, instability, and turnover of the H2-K(d) MHC class I molecule, J. Immunol., 181, 1978, 10.4049/jimmunol.181.3.1978 · DOI
  28. Tuli, 2009, Mechanism for amyloid precursor-like protein 2 enhancement of major histocompatibility complex class I molecule degradation, J. Biol. Chem., 284, 34296, 10.1074/jbc.M109.039727 · DOI
  29. DeVay, 2013, Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2), J. Biol. Chem., 288, 10805, 10.1074/jbc.M113.453373 · DOI · Paper page
  30. Russell, 1984, Domain map of the LDL receptor: sequence homology with the epidermal growth factor precursor, Cell, 37, 577, 10.1016/0092-8674(84)90388-X · DOI · Paper page
  31. Li, 2010, Genetic dissection of the amyloid precursor protein in developmental function and amyloid pathogenesis, J. Biol. Chem., 285, 30598, 10.1074/jbc.M110.137729 · DOI
  32. Lagace, 2006, Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice, J. Clin. Invest., 116, 2995, 10.1172/JCI29383 · DOI · Paper page
  33. Grefhorst, 2008, Plasma PCSK9 preferentially reduces liver LDL receptors in mice, J. Lipid Res., 49, 1303, 10.1194/jlr.M800027-JLR200 · DOI · Paper page
  34. Maxfield, 2004, Endocytic recycling, Nat. Rev. Mol. Cell Biol., 5, 121, 10.1038/nrm1315 · DOI · Paper page
  35. Basu, 1981, Monensin interrupts the recycling of low density lipoprotein receptors in human fibroblasts, Cell, 24, 493, 10.1016/0092-8674(81)90340-8 · DOI · Paper page
  36. Slunt, 1994, Expression of a ubiquitous, cross-reactive homologue of the mouse beta-amyloid precursor protein (APP), J. Biol. Chem., 269, 2637, 10.1016/S0021-9258(17)41992-2 · DOI
  37. Herz, 2001, LRP: a multifunctional scavenger and signaling receptor, J. Clin. Invest., 108, 779, 10.1172/JCI200113992 · DOI · Paper page
  38. Rashid, 2005, Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9, Proc. Natl. Acad. Sci. U. S. A., 102, 5374, 10.1073/pnas.0501652102 · DOI · Paper page
  39. Lillis, 2008, LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies, Physiol. Rev., 88, 887, 10.1152/physrev.00033.2007 · DOI · Paper page
  40. Shan, 2008, PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide, Biochem. Biophys. Res. Commun., 375, 69, 10.1016/j.bbrc.2008.07.106 · DOI · Paper page
  41. Vassar, 1999, Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE, Science, 286, 735, 10.1126/science.286.5440.735 · DOI · Paper page
  42. Gu, 2013, Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding, J. Lipid Res., 54, 3345, 10.1194/jlr.M041129 · DOI
  43. Browning, 2010, Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans, J. Lipid Res., 51, 3359, 10.1194/jlr.P009860 · DOI

Cited by

Sorted by citations

Metadata

Authors
Fu, T., Guan, Y., Xu, J., & Wang, Y.
Venue
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Publisher
Elsevier BV
Published
2017-09
Volume
1862
Issue
9
Pages
883-889
ISSN
1388-1981
DOI
10.1016/j.bbalip.2017.05.002
PMC
PMC5514539
Cited by
25
References
6
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • National Natural Science Foundation of China (31570807)
  • National Key Research and Development Program of China (2016YFA0500100)
  • 111 Project of China (B16036)
  • NIH (PO1HL20948, RO1HL092550)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review